Vir Biotechnology logo
Vir Biotechnology VIR
$ 11.45 1.2%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Vir Biotechnology Cost of Revenue | VIR

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Vir Biotechnology

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
26 K 845 K 2.76 M 146 M 65.9 M - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
146 M 26 K 43.2 M

Quarterly Cost of Revenue Vir Biotechnology

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - 11 K - - 50 K 52 K 59 K - 38 K 22 K 1.91 M - 22.3 M 27.9 M 90.1 M - 7.84 M 1.14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
90.1 M 11 K 12.6 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
Codexis Codexis
CDXS
9.34 M $ 1.42 0.33 % $ 124 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
49.4 M - - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
31.6 M - -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
12.2 M - 1.35 % $ 17.8 M chinaChina
CureVac N.V. CureVac N.V.
CVAC
106 M - - $ 867 M germanyGermany
Abcam plc Abcam plc
ABCM
91.2 M - - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
926 K - -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
58.4 M - 2.43 % $ 254 M germanyGermany
Ardelyx Ardelyx
ARDX
39.5 M $ 3.71 1.06 % $ 894 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
36.7 M $ 23.66 0.04 % $ 3.01 B usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
3.71 M - -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
515 K - - $ 12.5 M belgiumBelgium
Fortress Biotech Fortress Biotech
FBIO
20.9 M $ 2.71 0.04 % $ 75.6 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
49 M $ 21.0 2.08 % $ 301 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
47.5 M $ 208.35 0.16 % $ 10.4 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.85 M - 5.93 % $ 314 M canadaCanada
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
717 M $ 66.43 0.04 % $ 12.7 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
286 M - 0.49 % $ 251 B cayman-islandsCayman-islands